AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32579773
Drug: Topical platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical platelet gel (PG)
Trial: 32998324
Drug: Lutein (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein (12 mg)
Trial: 33292081
Drug: Topical refrigerant
RxNorm normalized name: Refrigerant 114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical refrigerant spray (TRS)
Trial: 35367525
Drug: Trametinib (1.0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib (1.0, 1.5, and 2.0 mg daily for 28 days) plus whole brain radiation therapy (WBRT, 37.5 Gy/15 fractions)
Trial: 36189534
Drug: Povidone iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone iodine solution
Trial: 36069869
Drug: Open-source automated
RxNorm normalized name: AMYLOPECTIN, UNSPECIFIED SOURCE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-source automated insulin delivery (AID) system
Trial: 33346789
Drug: 25 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg/day cannabidiol (CBD25)
Trial: 33346789
Drug: 50 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg/day cannabidiol (CBD50)
Trial: 39661119
Drug: Atrasentan 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan 0.75 mg/day
Trial: 32517390
Drug: Suprascapular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprascapular nerve pulsed radiofrequency (PRF) treatment
Trial: 35598122
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) + Taurine (NT) (500 mg Taurine + 150 mg NAC)
Trial: 35104607
Drug: Anodal high-definition
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal high-definition transcranial direct current stimulation (HD-tDCS) administered to the right inferior frontal gyrus (rIFG) for 5 consecutive days, twice a day.
Trial: 35104607
Drug: Sham HD-tDCS
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / pseudoephedrine hydrochloride Oral Solution [Spantuss HD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham HD-tDCS administered to the right inferior frontal gyrus (rIFG) for 5 consecutive days, twice a day.
Trial: 35458108
Drug: DGA +
RxNorm normalized name: Dextrose, Glutamine, and Arginine Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DGA + POTATO (17.5 g/day resistant starch)
Trial: 35458108
Drug: DGA +
RxNorm normalized name: Dextrose, Glutamine, and Arginine Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DGA + BAGEL (0 g/day resistant starch)
Trial: 34464517
Drug: BAY 1193397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 1193397 (single oral doses of 0.5-50 mg)
Trial: 34464517
Drug: BAY 1193397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 1193397 (single doses of 1 and 10 mg)
Trial: 34464517
Drug: BAY 1193397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 1193397 (multiple doses of 2 and 5 mg twice daily and 10 and 20 mg once daily for 9 consecutive days)
Trial: 35871702
Drug: 3% potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% potassium nitrate gel (UltraEZ)
Trial: 35871702
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBM) with a low-level infrared laser (100 mW, spot size of 0.028 cm2, dose of 1 J per point)
Trial: 35871702
Drug: 3% potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% potassium nitrate gel + PBM
Trial: 32075440
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IV acetaminophen and IV ketorolac
Trial: 35820741
Drug: Heat therapy
RxNorm normalized name: CVS Neck Arm & Leg Heat Therapy Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat therapy with natural thermal mineral water (38°C)
Trial: 34570798
Drug: Video of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video of Trump endorsing the vaccine
Trial: 32067288
Drug: 5-hydroxytryptophan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxytryptophan (50 mg daily for 4 weeks)
Trial: 33971278
Drug: 50,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 IU bolus dose of vitamin D plus 1000 IU daily supplement for six weeks
Trial: 33971278
Drug: 1000 IU
RxNorm normalized name: D 1000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU daily supplement alone
Trial: 34321042
Drug: Technology-supported sitting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technology-supported sitting balance therapy (12 sessions of 50 min over four weeks)
Trial: 34878659
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg IV every 3 weeks for ≤2 years)
Trial: 34878659
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m2 IV every week)
Trial: 33915251
Drug: Nab-paclitaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel (100 mg/m2 on days 1, 8, and 15 of a 21-day cycle)
Trial: 33915251
Drug: Docetaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m2 on day 1)
Trial: 35833913
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (clopidogrel plus aspirin)
Trial: 36184258
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg Atomoxetine (ATO) + 5 mg Oxybutynin (OXY)
Trial: 36440985
Drug: Pregabalin 300
RxNorm normalized name: pregabalin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 300 mg orally 2 hours before surgery
Trial: 36440985
Drug: Pregabalin 300
RxNorm normalized name: pregabalin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 300 mg orally
Trial: 34701225
Drug: 3D Conformal
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D Conformal Radiation Therapy (3DCRT)
Trial: 35429005
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive therapy (I‐CT) for 10 weeks
Trial: 35964063
Drug: Family-based Improvement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based Improvement for Health Literacy (FAMILY) intervention, which includes health literacy education interventions such as project preparation, core group building, promotion within family branch, and competition between family branches.
Trial: 32521976
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplementation (ONS) 2092 kJ/day, whole protein enteral nutrition for 90 days after discharge
Trial: 35761370
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 800 mg stat then 400 mg weekly
Trial: 33812327
Drug: NSAID +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID + magnesium (400 mg etodolac twice a day with 365 mg oral magnesium supplementation)
Trial: 33812327
Drug: NSAID alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID alone (400 mg etodolac twice a day)
Trial: 33812327
Drug: NSAID +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID + paracetamol (400 mg etodolac twice a day with 500 mg paracetamol twice a day)
Trial: 32179149
Drug: CMS loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMS loading dose (LD group) of 4 mg CBA/kg/dose
Trial: 32179149
Drug: Standard initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard initial dose (NLD group) of 2.5 mg (12-h interval) or 1.7 mg (8-h interval) of CBA/kg/dose
Trial: 32868437
Drug: Serological measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serological measures of transmission based on antibody response to S. mansoni soluble egg antigen (SEA)
Trial: 33506411
Drug: Diet supplemented
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet supplemented with 5 mg/kg of Se from SeGlu
Trial: 33506411
Drug: Diet supplemented
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet supplemented with 0.3 mg/kg of Se from sodium selenite (SS)
Trial: 32514756
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day of elemental zinc for three months
Trial: 34154634
Drug: Supervised training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised training of activities of daily living (ADL), resistance, and stability, twice a week for 1 hour per session
Trial: 34154634
Drug: Daily home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily home-based exercise representing regular outpatient care
Trial: 34028460
Drug: Intranasal beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal beclomethasone dipropionate + rhinophototherapy
Trial: 32948120
Drug: Singing group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Singing group intervention (34 bi-weekly sessions, 2 hours each for 4 months)
Trial: 36722208
Drug: Combination exercise
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination exercise
Trial: 36182594
Drug: EZ10/AS10 (ezetimibe/atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZ10/AS10 (ezetimibe/atorvastatin 10/10 mg FDC)
Trial: 36182594
Drug: EZ10/AS20 (ezetimibe/atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZ10/AS20 (ezetimibe/atorvastatin 10/20 mg FDC)
Trial: 36182594
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg (AS20)
Trial: 36182594
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg (AS40)
Trial: 32645934
Drug: WHEY-ALL (whey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHEY-ALL (whey protein, 3.1 µg B12/day)
Trial: 32645934
Drug: COLL (collagen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COLL (collagen, 1.3 µg B12/day)
Trial: 32645934
Drug: CARB (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CARB (maltodextrin, 0.3 µg B12/day)
Trial: 34426397
Drug: Oral ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ondansetron (0.1 mg/kg)
Trial: 32810504
Drug: Inhaled diesel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled diesel exhaust (DE) at 200 μg/m3
Trial: 32810504
Drug: Antioxidant pretreatment
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant pretreatment (1000 mg ascorbate for 7 days and 1200 mg N-acetylcysteine 1 day prior to exposure)
Trial: 36475905
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (3 doses of 2.7 × 10^6 PfSPZ)
Trial: 32141817
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg cholecalciferol
Trial: 32182747
Drug: DHA +
RxNorm normalized name: PNV-DHA + Docusate Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA + EPA supplementation (2.1 g/day of DHA + 240 mg/day of EPA)
Trial: 32301973
Drug: Autologous ADASC
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous ADASC implantation (G-1)
Trial: 32301973
Drug: Decellularized human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decellularized human corneal stroma (G-2)
Trial: 32301973
Drug: Autologous ADASCs
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous ADASCs + decellularized human corneal stroma (G-3)
Trial: 35045722
Drug: DPP4 inhibition
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP4 inhibition (sitagliptin) during ramipril treatment
Trial: 35045722
Drug: Aprepitant (NK1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (NK1 receptor blocker) during ramipril or valsartan treatment
Trial: 35045722
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during ramipril treatment
Trial: 35045722
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during valsartan treatment
Trial: 35045722
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during amlodipine treatment
Trial: 35045722
Drug: Sitagliptin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin + placebo during ramipril treatment
Trial: 35045722
Drug: Sitagliptin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin + placebo during valsartan treatment
Trial: 35045722
Drug: Sitagliptin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin + placebo during amlodipine treatment
Trial: 35045722
Drug: Sitagliptin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin + aprepitant during ramipril treatment
Trial: 35045722
Drug: Sitagliptin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin + aprepitant during valsartan treatment
Trial: 35045722
Drug: Sitagliptin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin + aprepitant during amlodipine treatment
Trial: 37286319
Drug: Treatment-as-usual (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (standard care).
Trial: 32496104
Drug: Group-administered stress
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-administered stress management with a trauma focus (SMT)
Trial: 32496104
Drug: Group-administered psychological
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-administered psychological first aid (PFA)
Trial: 34437779
Drug: Sham Treatment
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham Treatment
Trial: 32307650
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (EG) - intrabronchially inoculated with M. haemolytica (6.5×10^6 CFU/mL)
Trial: 35522618
Drug: Leap motion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leap motion control and conventional therapy
Trial: 33095139
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg ianalumab
Trial: 33095139
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg ianalumab
Trial: 36342163
Drug: Olpasiran 10
RxNorm normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpasiran 10 mg every 12 weeks
Trial: 36342163
Drug: Olpasiran 75
RxNorm normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpasiran 75 mg every 12 weeks
Trial: 36342163
Drug: Olpasiran 225
RxNorm normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpasiran 225 mg every 12 weeks
Trial: 36342163
Drug: Olpasiran 225
RxNorm normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpasiran 225 mg every 24 weeks
Trial: 33529342
Drug: CT (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT (control group with sterile saline solution)
Trial: 33529342
Drug: ST (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST (saline solution containing Salmonella Typhimurium)
Trial: 32819400
Drug: Adjunct treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct treatment
Trial: 34518033
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with choline fenofibrate and statin
Trial: 33125266
Drug: IGF-1 (insulin-like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF-1 (insulin-like growth factor 1)
Trial: 32682938
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone acetonide + 2% lidocaine hydrochloride
Trial: 32682938
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg triamcinolone acetonide + 2% lidocaine hydrochloride
Trial: 32682938
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (40 mg and 10 mg)
Trial: 35894410
Drug: Carbohydrate solution
RxNorm normalized name: phosphorated carbohydrate solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate solution (100 ml)
Trial: 35894410
Drug: Carbohydrate popsicle
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate popsicle (100 ml)
Trial: 33247691
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation of 6,000 IU (1.8 mg RAEs) per day
Trial: 33535899
Drug: Whole-Body Vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-Body Vibration (WBV) therapy, Compex-Winplate™, 3 sessions of 15 minutes per week for 8 weeks
Trial: 36433713
Drug: danuglipron 40-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: danuglipron 40-120 mg BID
Trial: 33741815
Drug: Upper limb
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper limb therapies after stroke
Trial: 35398192
Drug: Supportive resource
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive resource activation treatment (STARK)
Trial: 33458928
Drug: Pomegranate extract
RxNorm normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate extract nutraceutical (PE), 320 mg phenolics/day for 1 month
Trial: 33185527
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol (0.5%) cream, applied three times daily for three months
Trial: 34341578
Drug: Toripalimab plus
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab plus GP chemotherapy
Trial: 34341578
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus GP chemotherapy
Trial: 32204978
Drug: Curcumin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin group (receiving 100 mL of orange juice with 12 g of carrot and 2.5 g of turmeric after each dialysis session/week for 3 months)
Trial: 32083522
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day of MSM for 16 weeks
Trial: 32083522
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day of MSM for 16 weeks
Trial: 32819439
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus albumin (20 g in 100 mL) every 12 h for 4 days
Trial: 35223910
Drug: Spinal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal morphine (SM) 0.1 mg
Trial: 35223910
Drug: Bilateral landmark‐oriented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral landmark‐oriented TAP block with 20 ml of 0.25% bupivacaine
Trial: 34711232
Drug: umeclidinium/vilanterol 62.5/25
RxNorm normalized name: umeclidinium/vilanterol 62.5/25 MCG/INHAL Dry Powder Inhaler, 7 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: umeclidinium/vilanterol 62.5/25 µg once daily
Trial: 34711232
Drug: umeclidinium 62.5
RxNorm normalized name: UMECLIDINIUM 62.5MCG 7D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: umeclidinium 62.5 µg once daily
Trial: 34711232
Drug: salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmeterol 50 µg twice daily
Trial: 33704597
Drug: Early angiography
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early angiography and revascularization with guideline‐directed medical therapy
Trial: 32789516
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg D-Cycloserine (DCS)
Trial: 32789516
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg D-Cycloserine (DCS)
Trial: 33783470
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of oral atomoxetine
Trial: 34487919
Drug: Carrageenan-containing gel
RxNorm normalized name: Carrageenan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrageenan-containing gel
Trial: 34155082
Drug: Oral fat‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fat‐based energy‐dense supplement (300 kcal daily) for 12 weeks
Trial: 36123011
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg once daily for 24 months
Trial: 616388350
Drug: Amlodipine/atorvastatin (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/atorvastatin (Group 3)